GC041 Cough In A Chronic Smoker: COPD; Smoking Cessation
Chronic obstructive pulmonary disease (COPD) is a progressive, largely irreversible airflow limitation caused by chronic inflammatory response to inhaled irritants—predominantly tobacco smoke—necessitating smoking cessation as the single most effective intervention to slow disease progression.
COPD & Smoking Cessation — GC 041
Lecture Map
This lecture covers two tightly linked topics: Chronic Obstructive Pulmonary Disease (COPD) and Smoking Cessation. Tobacco smoke is the leading COPD exposure, and stopping it is the most important modifiable step for a person who smokes, but COPD can arise through multiple lifetime gene–environment pathways. The lecture walks through the full arc: what COPD is, why it happens, how to recognise it, how to investigate and manage it (both stable and acute), and then pivots to the pharmacology and psychology of quitting smoking. Understanding COPD from first principles — the distinction between small airway disease and parenchymal destruction, why controlled oxygen matters, and why cor pulmonale develops — is more useful than memorising drug lists.
"You will learn:
- the risk factors & pathophysiology of COPD
- the clinical features and complications of COPD
- the investigations & principles of management of COPD
- the psychology of smoking, the methods of and difficulties encountered in smoking cessation
- a clinical case study"
"COPD, a common preventable and treatable disease, is characterized by persistent respiratory symptoms and airflow limitation that are due to airway &/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients." — GOLD definition reproduced in the 2023 lecture [1]
Current wording: GOLD 2026 describes COPD as a heterogeneous lung condition with chronic respiratory symptoms due to airway (bronchitis/bronchiolitis) and/or alveolar (emphysema) abnormalities that cause persistent, often progressive airflow obstruction [13]. The newer wording deliberately recognizes non-tobacco causes, altered lung development and different biological pathways to the same clinical syndrome.
Let's unpack this definition because examiners love asking you to define COPD:
| Key phrase | Why it matters |
|---|---|
| "Common, preventable, treatable" | COPD is not curable, but it IS preventable (don't smoke) and treatable (bronchodilators, O₂, rehab). This framing is deliberate. |
| "Persistent respiratory symptoms" | Symptoms tend to be chronic or recurrent rather than purely episodic, but day-to-day variability does occur and symptom pattern alone does not separate COPD from asthma. |
| "Airflow limitation" | In a compatible clinical context, the spirometric hallmark is post-bronchodilator FEV₁/FVC < 0.70. |
| "Airway &/or alveolar abnormalities" | Two components: chronic bronchitis (airway) and emphysema (alveolar). |
| "Noxious particles or gases" | Smoking is by far #1, but also air pollution, biomass fuels, occupational dusts. |
| "Exacerbations and comorbidities" | These drive hospitalisation and mortality, not just the baseline lung function. |
2. Pathophysiology — Mechanisms of Airflow Limitation
The lecture explicitly teaches two mechanisms underlying airflow limitation: [1]
- Airway inflammation → mucosal oedema, neutrophilic infiltration
- Airway fibrosis, luminal plugs → structural narrowing of airways < 2mm diameter
- Increased airway resistance → harder to move air, especially on expiration
- Loss of alveolar attachments → the alveoli normally tether small airways open; when alveoli are destroyed, airways collapse during expiration
- Decrease of elastic recoil → the lung loses its ability to passively exhale; air gets trapped
Why does this matter? Because these two mechanisms explain everything downstream:
- Air trapping → hyperinflation → barrel chest, flattened diaphragm on CXR
- Destroyed alveoli → reduced gas exchange surface → low DLCO → hypoxaemia
- Chronic hypoxaemia → pulmonary vasoconstriction → pulmonary hypertension → cor pulmonale
"CB – chronic bronchitis: chronic cough + sputum" "E – emphysema: progressive dyspnoea"
The image is not presenting two mutually exclusive diseases. It maps bronchoconstriction, airway inflammation and mucus hypersecretion to cough/sputum, while loss of alveolar walls and elastic recoil produces exertional dyspnoea, air trapping and impaired gas transfer. These components commonly coexist. Avoid the obsolete “blue bloater/pink puffer” stereotypes: body habitus, cyanosis and CO₂ retention are not reliable ways to phenotype an individual.
- Chronic bronchitis is a clinical syndrome (classically productive cough for ≥3 months in each of 2 successive years after excluding other causes); it does not by itself prove spirometric COPD.
- Emphysema is a pathological/radiological description of alveolar destruction; emphysema can be visible on CT before the spirometric threshold for COPD is crossed.
"Affects ~10% of Hong Kong elderly > 70 years old; overall occupied ~10% public medical bed days; expected increasing incidence because of smoking and worsening air pollution — a very common medical condition!" [1]
These figures are reproduced for lecture context and may reflect the data available when the slide was prepared; do not quote them as current Hong Kong prevalence or bed-use estimates without a dated local source. The durable teaching point is that COPD creates substantial morbidity, hospital use and mortality.
4. Risk Factors
The lecture lists risk factors divided into Environmental Factors and Host Factors: [1]
| Factor | Notes |
|---|---|
| Cigarette smoking | "By far the most important factor accounting for > 85% patients" [1] |
| Air pollution | Outdoor particulate matter |
| Passive smoking | Second-hand smoke exposure |
| Indoor biomass combustion | "e.g. wood — especially women in rural regions/countries" [1] — this explains why non-smoking women in developing countries get COPD |
| Occupational dusts, fumes and chemicals | Risk accumulates with intensity and duration of exposure |
| Early-life and developmental factors | Prematurity, impaired lung growth, childhood respiratory disease and accelerated lung ageing can lead to low peak lung function or earlier obstruction [13] |
| Factor | Notes |
|---|---|
| α₁-antitrypsin (AAT) deficiency | The lecture highlights young-onset emphysema, but current guidance recommends testing all people with COPD regardless of age or ethnicity, usually once, because demographics cannot rule it out [19]. |
First-principles explanation of AAT deficiency: α₁-antitrypsin is a liver-produced protease inhibitor that protects lung tissue from neutrophil elastase. Tobacco smoke increases the protease burden and impairs antiprotease defence. Severe inherited deficiency (classically Pi*ZZ) permits accelerated alveolar-wall destruction → often panacinar, basal-predominant emphysema, in contrast to the usual upper-zone centrilobular pattern of smoking-related emphysema. Presentation is variable across ages and ancestries.
Exam Trap: AAT Deficiency
Smoking-related emphysema is often centrilobular and upper-zone predominant, whereas severe AAT deficiency classically causes panacinar, basal-predominant emphysema. Young age, little smoking, basal disease, bronchiectasis or family/liver history should heighten suspicion—but do not restrict testing to that stereotype [19].
5. Clinical Presentations
"Typically: Middle age / elderly, men > women; Nearly always Hx of chronic smoking; Chronic cough and sputum: years! (usually whitish and mucoid unless exacerbations) – (CB); Progressive shortness of breath – (E); Features of Complications → hospitalization" [1]
This is the lecture’s traditional case profile, not a diagnostic rule. COPD also occurs in women, never-smokers, younger adults with abnormal lung development, and people exposed to biomass fuel, air pollution or occupational hazards [13].
- Smoking history: Always quantify in pack-years = (packs/day) × (years smoked). A "chronic smoker of one pack per day since teenage" (as in the 2024 SAQ [7]) is roughly 40+ pack-years.
- Cough character: Chronic, with or without sputum. A change in sputum colour, volume or viscosity during clinical deterioration supports an exacerbation and may increase suspicion of bacterial infection, but colour alone is not proof.
- Dyspnoea: Progressive, initially exertional, eventually at rest. Grade using mMRC dyspnoea scale [2]:
| mMRC Grade | Description | Memory Aid |
|---|---|---|
| 0 | SOB only during strenuous exercise | |
| 1 | SOB when walking uphill | 斜 (slope) |
| 2 | Walks slower than peers due to SOB | 慢 (slow) |
| 3 | Stops for breath after walking a few minutes | 分 (minutes) |
| 4 | Too breathless to leave the house | 街 (street) |
- Exacerbation history: How many per year? Required hospitalisation? Required NIV/ICU?
- Occupational history: Construction worker, mining, biomass exposure
- Comorbidities: Cardiac disease, depression, osteoporosis (see Section 11)
General inspection:
- Cyanosis (central → severe hypoxaemia)
- Nicotine staining of fingers [1]
- Use of accessory muscles (sternocleidomastoid, scalenes)
- Pursed-lip breathing (creates auto-PEEP to keep airways open)
- Cachexia (in advanced emphysema)
Chest:
- Barrel chest (increased AP diameter from hyperinflation)
- Reduced chest expansion (hyperinflated lungs can't expand further)
- Hyper-resonant percussion (air-filled)
- Reduced breath sounds (poor air entry)
- Wheeze (airway narrowing)
- Prolonged expiratory phase
Signs of complications:
- Cor pulmonale: raised JVP, parasternal heave (RVH), ankle oedema, loud P2, hepatomegaly [1]
- Asterixis/flapping tremor (CO₂ retention)
- Bounding pulse, warm peripheries (CO₂ retention → vasodilation)
6. Complications of COPD
The lecture provides a diagram showing: Chronic hypoxaemia → Pulmonary hypertension → RVH & RVF
Here's the logic chain:
- Destroyed alveoli + V/Q mismatch → chronic hypoxaemia
- Hypoxaemia → hypoxic pulmonary vasoconstriction (Euler-Liljestrand reflex — pulmonary arterioles constrict in response to low alveolar PO₂ to redirect blood to better-ventilated areas)
- When hypoxaemia is global (as in severe COPD), vasoconstriction is diffuse → pulmonary hypertension
- RV pumps against high pulmonary pressure → RV hypertrophy (RVH)
- Eventually RV fails → right ventricular failure (RVF) = cor pulmonale
"Pulmonary HT → RV suffers; cf. Systemic HT → LV suffers" [1]
Signs of cor pulmonale (from the diagram) [1]:
- Raised JVP (back-pressure from failing RV)
- Ankle oedema (systemic venous congestion)
- Parasternal heave (RVH)
- Note: Pulmonary oedema is NOT typically a feature (that's LVF)
Management of cor pulmonale [1]:
- Diuretics when there is clinically significant venous congestion; titrate cautiously because excessive preload reduction can worsen haemodynamics
- Individualise salt/fluid advice rather than imposing routine severe restriction
- Long-term oxygen therapy (treats the underlying cause — hypoxaemia)
- Acute exacerbation (see Section 9) — may involve any combination of:
- Pneumothorax
- Increased airflow obstruction
- Infection
- Respiratory failure
- Chronic respiratory failure (Type I or Type II)
- Pulmonary thromboembolism — immobility + polycythaemia + inflammation = prothrombotic state
- Secondary polycythaemia — chronic hypoxaemia → EPO release → elevated haematocrit (> 55%)
- Pneumothorax — bullae rupture
7. Investigations
The lecture lists: [1]
| Investigation | What You're Looking For | Why |
|---|---|---|
| Lung function test (Spirometry) | FEV₁/FVC < 0.70 post-bronchodilator (persistent obstruction); lung volumes may show ↑RV/TLC (gas trapping/hyperinflation); ↓DLCO supports loss of gas-exchange surface or pulmonary vascular disease | Spirometry is mandatory in the appropriate clinical context [13]. DLCO helps phenotype disease but is neither required nor specific enough to “distinguish COPD from asthma” by itself. |
| Complete blood counts | Polycythaemia (↑Hct, ↑Hb) | Secondary polycythaemia from chronic hypoxaemia |
| Chest X-ray | Hyperinflation (> 6 anterior ribs visible, flattened diaphragm, increased retrosternal airspace); Hypertranslucency (dark lungs from destroyed alveoli and air trapping) | Also look for cardiomegaly + prominent pulmonary arteries if cor pulmonale |
| Arterial blood gases | Type I (↓PaO₂, normal/↓PaCO₂) or Type II respiratory failure (↓PaO₂, ↑PaCO₂) | Essential for assessing severity and guiding oxygen therapy |
| Sputum examination | Culture & sensitivity during exacerbations | Identify causative organism for targeted antibiotics |
| ECG ± Echocardiogram | P pulmonale (peaked P waves in II), right axis deviation, RVH, RVSP elevation | Assess for cor pulmonale |
The lecture shows two CXR slides:
- Uncomplicated COPD: Hyperinflated, relatively hyperlucent lungs with low/flattened diaphragms and a long, narrow cardiac silhouette.
- COPD with suspected pulmonary hypertension/cor pulmonale: hyperinflation plus enlarged central pulmonary arteries and cardiac enlargement [1]. These signs suggest the complication; CXR does not measure pulmonary pressure or prove RV failure, so correlate with examination, ECG and echocardiography.
Reading the Images: What CXR Can and Cannot Do
The films visually explain the mechanics of emphysema—more retained air makes the lungs darker and pushes the diaphragms down. A normal CXR does not exclude COPD, and hyperinflation is not specific. Use CXR mainly to identify complications or alternatives such as pneumonia, pneumothorax, heart failure or a mass.
The lecture also shows an axial non-contrast CT chest demonstrating:
- Extensive bilateral areas of markedly increased lucency / low attenuation
- Large, thin-walled upper-lobe bullae occupying substantial hemithoracic volume, with sparse attenuated vessels and compressed residual lung [1]
- Bullae can further impair mechanics and can rupture, causing secondary spontaneous pneumothorax
CT is more sensitive than CXR for detecting and mapping emphysema and is important when symptoms and spirometry are discordant or when considering lung volume reduction procedures. A low-attenuation CT alone does not replace post-bronchodilator spirometry for diagnosing COPD [13].
The displayed case is labelled “very severe COPD,” and the image provides more information than the ratio alone:
- FEV₁: 0.47 L (25% predicted) before and 0.50 L (27% predicted) after bronchodilator
- FVC: 1.18 L (47% predicted) before and 1.22 L (48% predicted) after bronchodilator
- FEV₁/FVC: 0.39 before and 0.41 after bronchodilator
- The expiratory limb is markedly scooped/concave with a low peak flow, visually demonstrating expiratory flow limitation.
- DLCO: 32% predicted, supporting substantial gas-transfer impairment and an emphysema component in this clinical setting.
There is little acute bronchodilator response on this test, but reversibility is variable and should not be used alone to distinguish COPD from asthma. Also note that the displayed lung-volume values do not demonstrate increased TLC; do not infer hyperinflation simply because the diagnosis is COPD.
| GOLD Stage | FEV₁ (% predicted, post-bronchodilator) |
|---|---|
| GOLD 1 (Mild) | ≥ 80% |
| GOLD 2 (Moderate) | 50–79% |
| GOLD 3 (Severe) | 30–49% |
| GOLD 4 (Very severe) | < 30% |
Key point: In a compatible clinical context, post-bronchodilator FEV₁/FVC < 0.70 confirms persistent airflow obstruction, then FEV₁ % predicted grades its spirometric severity [13]. The fixed 0.70 threshold may overdiagnose some older adults and underdiagnose some younger adults, so borderline results require clinical interpretation and sometimes comparison with the lower limit of normal or repeat spirometry.
After grading airflow obstruction (GOLD 1–4), the GOLD framework classifies patients into Groups A, B, or E based on symptoms and exacerbation history:
| Lower symptoms (mMRC 0–1 / CAT < 10) | Higher symptoms (mMRC ≥ 2 / CAT ≥ 10) | |
|---|---|---|
| Higher exacerbation risk (≥ 2 moderate exacerbations/year OR ≥ 1 leading to hospitalisation) | Group E | Group E |
| Lower exacerbation risk (0–1 moderate exacerbation, not leading to hospitalisation) | Group A | Group B |
Initial Pharmacological Treatment by Group [1]
| Group | Initial Treatment |
|---|---|
| A | A bronchodilator (short- or long-acting) |
| B | LABA + LAMA (single inhaler preferred) |
| E | LABA + LAMA; consider LABA + LAMA + ICS if blood eosinophils ≥ 300 |
"Single inhaler therapy may be more convenient and effective than multiple inhalers." [1]
| Feature | COPD | Chronic Asthma | Bronchiectasis |
|---|---|---|---|
| Smoking/exposure | Common, but not required | May be present or absent | May be present or absent |
| Age of onset | Middle age/elderly | Often childhood | Often childhood/young |
| Symptoms | Persistent, progressive | Episodic, with symptom-free intervals | Chronic productive cough |
| Sputum | Mucoid (unless exacerbation) | Usually minimal | Purulent, large volume, foul-smelling |
| Clubbing | Absent | Absent | Present |
| Bronchodilator response | Variable; persistent post-BD obstruction required for diagnosis | Variable; a marked response supports asthma but absence does not exclude it | Variable |
| DLCO | ↓ (if emphysema) | Normal | Normal or ↓ |
| CXR | Hyperinflation, hypertranslucency | Usually normal between attacks | Tramlines, ring shadows |
8. Management of Stable COPD
The lecture outlines a Management Program: [1]
- Assess and monitor disease
- Reduce risk factors: stop smoking
- Manage stable COPD: Bronchodilator (BD), Inhaled Corticosteroids (ICS), Long-term Oxygen Therapy (LTOT), Rehabilitation
- Manage exacerbation: Controlled oxygen therapy, Antibiotics, Systemic steroid, Non-invasive Ventilation (NIV)
- End stage COPD: Lung Volume Reduction Procedures / Lung Transplantation
- Smoking cessation is the most important modifiable intervention for people who smoke: it reduces ongoing exposure, slows accelerated loss of lung function and improves prognosis. Avoid the older absolute claim that it is the only treatment that changes outcomes; selected inhaled regimens, vaccination, rehabilitation and LTOT in severe chronic hypoxaemia affect important clinical outcomes.
- See Section 10 for detailed smoking cessation pharmacology
"Bronchodilators (BD): Anti-cholinergics, β₂ agonists. Anti-inflammatory Rx: Inhaled corticosteroids (ICS); New oral phosphodiesterase inhibitor (Roflumilast) — when frequent exacerbations. Inhaled preferred." [1]
| Drug Class | Short-Acting (Relief) | Long-Acting (Maintenance) | Mechanism |
|---|---|---|---|
| β₂ agonists | Salbutamol (Ventolin), Terbutaline (Bricanyl) | Salmeterol (Serevent), Formoterol (Oxis) | Stimulate β₂ receptors → bronchial smooth muscle relaxation → bronchodilation |
| Anti-cholinergics | Ipratropium (Atrovent) | Tiotropium (Spiriva) | Block muscarinic (M3) receptors → prevent ACh-mediated bronchoconstriction → bronchodilation |
| ICS | — | Beclomethasone, Budesonide, Fluticasone | In an appropriate combination and selected patient, reduces exacerbations; not routine COPD monotherapy and increases pneumonia risk |
| PDE4 inhibitor | — | Roflumilast (Daxas) | "A new oral non-steroid anti-inflammatory therapy specific for COPD" [1] — inhibits PDE4 → ↑cAMP → anti-inflammatory. Used when FEV₁ < 50% + chronic bronchitis phenotype [2] |
ICS in COPD — Important Nuance
Unlike asthma, ICS monotherapy is not routine COPD treatment. An ICS-containing combination is considered mainly for exacerbation prevention, with likely benefit increasing as blood eosinophils rise; if asthma coexists, an ICS is required. Balance this against adverse effects including pneumonia [13]. Roflumilast is a selected add-on—not a general bronchodilator—principally for severe airflow obstruction with chronic bronchitis and recurrent exacerbations despite appropriate inhaled therapy.
The photographs show that selecting a drug is not enough: the delivery device is part of the prescription.
- A pressurised metered-dose inhaler needs coordinated slow inhalation unless used with a spacer; a dry-powder device needs a sufficiently forceful, deep inhalation.
- The capsule placed in a HandiHaler-type device is pierced and inhaled—it is not swallowed.
- At initiation and follow-up, demonstrate technique, ask the patient to show it back, check adherence and confirm that dexterity, cognition and inspiratory flow suit the device. Current NICE quality standards call for technique assessment when starting/changing treatment and at least annually [14].
"Exercise Training: Improves muscle function and increases exercise tolerance; Reduces dyspnoea; Improves quality of life" [1]
Pulmonary rehabilitation is a multidisciplinary programme including [1]:
- Physiotherapy
- Muscle/exercise training
- Nutritional support ("for cachexia" [1])
- Education
- Psychotherapy
- Ventilatory assistance
- Home care
This is a non-pharmacological intervention that is frequently tested in SAQs [2].
The rehabilitation photograph makes the programme concrete: lower-limb endurance work on cycle ergometers is combined with seated upper-limb/resistance exercise in a supervised group. It is not simply “chest physiotherapy”; it is a comprehensive, individually tailored programme of exercise, education and behaviour change.
"+ flu vaccine" [1]
- Keep influenza, pneumococcal, COVID-19 and other indicated vaccines up to date according to the current Hong Kong schedule and individual risk profile. Avoid memorising the older universal “PCV13 + PPV23” sequence because available products and schedules change.
Criteria for LTOT in COPD: [1]
- "Resting PaO₂ < 7.3 kPa by two separate measurements when breathing room air in stable condition on optimal medical treatment"
- "Resting PaO₂ < 8 kPa (i.e. relaxing the criteria) when in addition the patient has:
- Secondary polycythaemia (haematocrit > 55%)
- Cor pulmonale
- Pulmonary hypertension
- Nocturnal hypoxaemia"
Current-practice correction: Assess in a stable patient on optimal therapy using ABGs on 2 occasions at least 3 weeks apart. Consider LTOT at PaO₂ < 7.3 kPa, or at 7.3–8.0 kPa with secondary polycythaemia, peripheral oedema or pulmonary hypertension [14]. Do not offer LTOT for isolated nocturnal hypoxaemia caused by COPD [14]. Local protocols and specialist oxygen assessment govern final prescribing.
Practical points from the lecture [1]:
- Oxygen flow is prescribed and titrated for rest, sleep and exertion; patients should not self-adjust it.
- Current minimum supported duration is at least 15 hours/day [14]. The lecture/past-paper wording “16–18 hours including bedtime” remains compatible with that minimum but should be recognised as historical exam phrasing.
- Delivered via O₂ concentrator ("an electrical appliance; a molecular sieve that takes and concentrates O₂ from air → non-stop supply; patient can buy or rent" [1])
- The slide’s portable-concentrator weights and battery durations are examples, not specifications: devices differ, and pulse-dose delivery may not meet every patient’s need. Assess and titrate using the actual device, with a power/backup and travel plan.
- Fire safety is inseparable from LTOT: no smoking or open flame near oxygen, keep equipment away from heat sources and address trip hazards. Ongoing smoking creates a major burn/fire risk [14].
2022 MCQ: LTOT Duration
Q: A 75-year-old man with COPD was advised home oxygen therapy. What is the MOST APPROPRIATE therapy? A (historical exam wording): Home oxygen therapy at least 16–18 hours a day including bedtime [6]. Current guidance states at least 15 hours/day; oxygen is prescribed for qualifying chronic hypoxaemia, not simply “as needed” for breathlessness [14].
2024 MCQ: Cor Pulmonale and Survival Benefit
Q: A 68-year-old man with COPD has features of cor pulmonale, SaO₂ 90% on room air. Which contributes the BEST survival benefit? A: Long-term oxygen therapy [7] if formal chronic-hypoxaemia criteria are met. Cor pulmonale alone with a single borderline saturation does not substitute for stable ABG assessment. LTOT improves survival in selected patients with severe chronic resting hypoxaemia [14].
9. Management of Acute Exacerbation of COPD (AECOPD)
"Management of complications — which account for most of the hospitalizations & mortality" [1]
- Infection (~70%): viral (rhinovirus, influenza) or bacterial
- Air pollution
- Unknown (~30%)
Before labelling deterioration as AECOPD, actively consider pneumonia, pneumothorax, acute heart failure/arrhythmia and pulmonary embolism. These can mimic or aggravate an exacerbation and require different treatment [13].
Management of AECOPD (from lecture) [1]
Controlled O₂ therapy; Exclude and treat pneumothorax; Systemic corticosteroid; ↑Inhaled bronchodilators; Antibiotics for infections; Non-invasive ventilation for decompensated type II respiratory failure [1]
"Aim: to use O₂ in a controlled manner to achieve a target PaO₂ of 8 kPa (SaO₂ > 90%) without significant CO₂ retention or acidosis" [1]
Why “controlled”? Excess oxygen can worsen hypercapnia and acidosis in susceptible patients. The main mechanism is worsening V/Q mismatch when oxygen reverses hypoxic pulmonary vasoconstriction in poorly ventilated lung; the Haldane effect and a smaller fall in ventilation may also contribute. “Removing the hypoxic drive” alone is an incomplete and misleading explanation [16]. Treat hypoxaemia, but titrate oxygen and recheck blood gases.
Modes: Nasal cannula (1–2 L/min); Venturi mask (24%, 28%) [1]
Venturi masks deliver a precise FiO₂ regardless of respiratory pattern — this is why they're preferred in COPD exacerbations over simple face masks (which deliver variable and often excessive FiO₂).
Monitor: Clinical (conscious levels, blood pressure, pulses); Pulse oximetry; Arterial blood gas measurement [1]
During an acute exacerbation in a patient at risk of hypercapnic respiratory failure, target SpO₂ 88–92% while blood gases are assessed, unless an individualised target is documented [14][16]. Pulse oximetry cannot reveal PaCO₂ or pH.
Exam Trap: Oxygen in COPD
"Commonest sputum bacterial isolates: Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, (Pseudomonas aeruginosa)" [1]
Pseudomonas is in brackets because it's more relevant in severe/frequent exacerbators and those with bronchiectasis overlap.
"Choice of empirical antibiotics is usually clinical, basing on knowledge of local bacterial & resistance pattern" [1] Examples: augmentin, macrolide, cephalosporin [1]
The slide’s rule “≥2 cardinal symptoms” is too broad if neither is purulence. A commonly used GOLD indication is [13]:
- Increased dyspnoea
- Increased sputum volume
- Purulence of sputum
- Give antibiotics when all 3 are present, or when 2 are present and purulence is one of them, or when invasive/non-invasive mechanical ventilation is required.
- NICE instead emphasises overall severity, especially sputum colour/volume/thickness, prior cultures and admissions, complication risk and antimicrobial resistance [15]. Follow local Hong Kong antimicrobial guidance rather than memorising a generic drug list.
- Obtain sputum culture in severe/frequent exacerbations, prior resistant organisms, suspected bronchiectasis/Pseudomonas or failure to respond.
A typical adult regimen is prednisone-equivalent 40 mg daily for 5 days [13]. Oral therapy is generally as effective as IV therapy when the patient can absorb oral medication; longer courses increase harm and are not routine.
"NIV for COPD Type II Respiratory Failure — tightly fit to minimize air leak; no intubation, hence 'non-invasive'; intubation & IPPV when NIV fails" [1]
Indication: Persistent acute hypercapnic ventilatory failure with respiratory acidosis despite optimal initial medical therapy [14]. Interpret the ABG, work of breathing, mental state and trajectory together; NIV must be delivered where staff can monitor response and promptly intubate if it fails or an immediate invasive airway is required.
How NIV works: Bilevel positive airway pressure (BiPAP) provides:
- IPAP (inspiratory positive airway pressure) → augments tidal volume → improves alveolar ventilation → washes out CO₂
- EPAP (expiratory positive airway pressure) → splints airways open → counteracts auto-PEEP → reduces work of breathing
Failure of NIV → reassess reversible causes and escalate promptly to intubation/IPPV when appropriate. The mask photograph shows a close-fitting full-face interface connected to a ventilator; obtain a seal without excessive strap pressure, protect skin and monitor leak, synchrony, gases and consciousness.
10. Smoking Cessation
"> 4,000 chemicals; > 40 carcinogens; Nicotine (addiction → brain); CO (heart)" [1]
Treat the numerical counts as an older educational shorthand; the enduring distinction is that nicotine principally drives dependence, while toxic products of combustion cause most smoking-related cancer, cardiovascular and respiratory harm. Carbon monoxide also reduces oxygen carriage by forming carboxyhaemoglobin.
"Addiction, stimulation; Atherosclerosis (hardening); Stimulation (adrenaline & NA); Nicotine nail staining — Important in Smoking cessation" [1]
Nicotine acts on nicotinic acetylcholine receptors (nAChR) in the brain, particularly in the mesolimbic dopamine pathway (ventral tegmental area → nucleus accumbens). It releases dopamine → reward → reinforcement → addiction. This is why smoking cessation is so difficult — it's not just a "habit", it's a neurochemical addiction.
The image compresses whole-smoke harms into “nicotine.” More precisely, nicotine causes dependence and acute sympathomimetic effects, but do not attribute atherosclerosis, cancer and chronic lung injury to nicotine alone; those risks arise predominantly from the complete tobacco-smoke exposure.
"Fletcher's graph: Decline of FEV₁ with age and smoking habits — It's never too late to quit" [1]
This is a classic, high-yield graph. Key points:
- Non-smokers lose FEV₁ gradually with age (normal ageing)
- Susceptible smokers lose FEV₁ much faster → cross the disability/death threshold earlier
- If you quit smoking at any point, the rate of FEV₁ decline returns towards that of non-smokers (you don't regain lost function, but you stop the accelerated loss)
- This is why the lecture says "it's never too late to quit" — even in established COPD, quitting improves prognosis
Read the curves as a schematic population model, not a prediction of an individual’s exact FEV₁ or age of disability. The visual message is that stopping earlier preserves more lung function, while stopping later still reduces future excess decline.
The lecture mentions withdrawal symptoms include:
- Craving
- Coughing
- Hunger / weight gain
- Bowel disturbance
- Sleep disturbance
- Dizziness
- Paraesthesia
- Mood swings, irritability
- Lack of concentration [3]
Three options:
- Nicotine — gum, patch, inhaler
- Bupropion SR (Zyban/Wellbutrin SR) — antidepressant with specific use in smoking cessation
- Varenicline (Champix) — acts at the same receptor in the brain as nicotine (ACh receptor) — dual action: ↓withdrawal S/S when quitting; blocks the reinforcing effects of nicotine when smoking
Plus: health care professional counselling; social support by family & friends
"Success rate at 1 year only about 20–35%! Efficacy: Varenicline: best" [1]
| Agent | Mechanism | Key Points |
|---|---|---|
| Nicotine replacement | Provides nicotine without tobacco combustion products → reduces withdrawal symptoms | A long-acting patch plus short-acting gum/lozenge/spray is more effective than either alone; demonstrate gum “chew-and-park” technique and patch use. |
| Bupropion (Zyban) | NE-DA reuptake inhibitor + nicotinic antagonist [3] | An antidepressant repurposed for smoking cessation. Reduces craving and withdrawal. CI: seizure history. |
| Varenicline (Champix) | Partial agonist at α₄β₂ nAChR | Dual action: partial receptor stimulation reduces withdrawal while competitive occupancy reduces nicotine reward. Start before the quit date and counsel about adverse effects. |
| Cytisine/cytisinicline | Nicotinic partial agonist | Also recommended by WHO where licensed and available [17]. |
Current approach: Combine pharmacotherapy with behavioural support and shared decision-making. WHO recommends varenicline, NRT, bupropion and cytisine as effective adult treatments [17]. NICE considers varenicline, combination NRT and cytisinicline among the more effective licensed options when paired with behavioural support, while single-form NRT and bupropion are generally less effective [18]. Choose according to preference, contraindications, previous response, interactions, availability and local protocol—not a universal one-line ranking.
Past-Paper Caution: Do Not Generalise One Scenario
The 2022 question later reproduced in this note compares counselling plus NRT, bupropion and varenicline in a patient with severe CAD awaiting intervention [6]. Use the official answer key for that historical question. For present practice, do not treat “CAD = one mandatory cessation drug” or “varenicline is always best” as a rule; pair behavioural support with an individually appropriate evidence-based medicine [17][18].
Reasons people smoke:
- Overlearnt habit, association/secondary reinforcement
- Routine, social-peer pressure
- Craving / addiction (nicotine)
- Stress relief, relaxation
Potential motivators for cessation:
- Save money
- Social acceptability
- Not harm others (passive smoking)
- Improve health
- Better taste and smell
- Reduce fire hazard
Key counselling principle: Allow the smoker to find a personal reason for quitting [3]. This is more effective than lecturing.
The 2016 SAQ asked about the six MPOWER measures:
- M — Monitor tobacco use and prevention policies
- P — Protect people from tobacco smoke
- O — Offer help to quit tobacco use
- W — Warn about the dangers of tobacco
- E — Enforce bans on tobacco advertising, promotion, sponsorship
- R — Raise taxes on tobacco
The lecture lists common comorbidities in COPD: [1]
This was directly tested in the 2024 SAQ [7]: "Name five cardiorespiratory co-morbid conditions" and "Name five non-cardiorespiratory co-morbid conditions."
| Cardiorespiratory | Non-Cardiorespiratory |
|---|---|
| Cardiovascular disease (CVD) | Osteoporosis |
| Heart failure | Anxiety and depression |
| Ischaemic heart disease (IHD) | Metabolic syndrome and diabetes |
| Arrhythmias | Gastroesophageal reflux (GERD) |
| Peripheral vascular disease | Obstructive sleep apnea |
| Hypertension | |
| Lung cancer | |
| Bronchiectasis |
Why so many comorbidities? The clustering is multifactorial: shared exposures (especially smoking), ageing, inactivity/deconditioning, systemic inflammatory pathways and treatment effects all contribute. Do not assume every comorbidity is caused by COPD. For example:
- Smoking → atherosclerosis → IHD, PVD, stroke
- Systemic inflammation → metabolic syndrome, diabetes
- Corticosteroid use + inactivity → osteoporosis
- Chronic illness + breathlessness + social isolation → anxiety and depression
- Smoking → lung cancer (COPD itself is an independent risk factor for lung cancer)
- GERD → microaspiration → exacerbations
"End stage COPD: Lung Volume Reduction Procedures / Lung Transplantation" [1]
- Lung Volume Reduction Surgery (LVRS): Removes the most diseased, hyperinflated portions of lung → allows remaining lung to expand better → improves diaphragm mechanics. Best for upper-lobe-predominant emphysema with low exercise capacity.
- Lung transplantation: For highly selected patients with very severe COPD refractory to all other treatments.
- GC 077 (Pleural effusion in a chronic smoker) [9]: The same population of chronic smokers may present with lung cancer → pleural effusion. Always consider malignancy in the differential of a smoker with new respiratory symptoms.
- GC 052 (Fever and purulent sputum) [10]: COPD patients are prone to community-acquired pneumonia (H. influenzae, S. pneumoniae). Know the overlap between AECOPD and pneumonia.
- GC 084 (Shortness of breath on exertion) [11]: Heart failure is a major differential and comorbidity of COPD. Both cause exertional dyspnoea. Look for orthopnoea, PND, bilateral basal crackles (HF) vs barrel chest, wheeze, hyperinflation (COPD).
- CFB MED03 (Respiratory System) [12]: Cough classification — acute (days: URTI, pneumonia), subacute (weeks: TB, lung cancer), chronic (years: COPD, bronchiectasis, asthma).
High Yield Summary
-
COPD
- = chronic respiratory symptoms from airway and/or alveolar abnormalities with persistent, often progressive obstruction; confirm in context with post-BD FEV₁/FVC < 0.70.
- Smoking is the leading exposure, but biomass, occupational/environmental exposure, abnormal lung development and genetic factors also matter.
- Complications: cor pulmonale (chronic hypoxaemia → pulmonary HT → RVF), respiratory failure, pneumothorax, polycythaemia.
-
Investigations
- Spirometry confirms persistent obstruction. CXR looks for hyperinflation, complications and alternatives; CBC for polycythaemia; ABG for gas exchange; ECG/echo for right-heart effects. A low DLCO supports emphysema or pulmonary vascular impairment but is not diagnostic alone.
-
Management
- (1) Smoking cessation — the most important exposure-modifying intervention; pair behavioural support with an individualised evidence-based medicine
- (2) Bronchodilators (anti-cholinergics + β₂ agonists)
- (3) Add ICS for frequent exacerbators
- (4) Pulmonary rehabilitation
- (5) LTOT after stable formal assessment if PaO₂ < 7.3 kPa (or 7.3–8.0 kPa with specified hypoxic complications) — ≥15 h/day — improves survival in severe chronic resting hypoxaemia.
-
AECOPD
- Exclude mimics; controlled O₂ (target SpO₂ 88–92% while gases are assessed), short-acting bronchodilators, short-course systemic steroid, antibiotics when bacterial features/ventilation indicate, and NIV for persistent acute hypercapnic acidosis.
-
Comorbidities
- CVD, IHD, HF, lung cancer, osteoporosis, depression, diabetes, GERD, OSA — frequently examined (2024 SAQ).
Active Recall - COPD & Smoking Cessation
[1] Lecture slides: GC 041. Cough in a chronic smoker_COPD; smoking cessation.pdf [2] Senior notes: Maksim Medicine Notes.pdf (Respiratory medicine section) [3] Senior notes: Ryan Ho Respiratory.pdf (Management of COPD, Smoking cessation) [4] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (COPD differential diagnosis section) [5] Past papers: 2016 Fourth Summative SAQ.pdf (Question 11 - MPOWER) [6] Past papers: 2022 Fourth Summative MCQ.pdf (Questions 44, 45); 2022 Fourth Summative Minicase.pdf (Case Three); 2022 Fourth Summative SAQ.pdf (Question 6) [7] Past papers: 2024 Fourth Summative SAQ.pdf (Question 4); 2024 Fourth Summative MCQ.pdf (Question 34) [9] Lecture slides: GC 077. Pleural effusion in a chronic smoker.pdf [10] Lecture slides: GC 052. Fever and purulent sputum.pdf [11] Lecture slides: GC 084. Shortness of breath on exertion.pdf [12] Lecture slides: CFB (MED03) Respiratory System.pdf [13] Global Initiative for Chronic Obstructive Lung Disease. GOLD 2026 Report. [14] National Institute for Health and Care Excellence. COPD in over 16s: diagnosis and management (NG115). [15] National Institute for Health and Care Excellence. COPD acute exacerbation: antimicrobial prescribing (NG114). [16] British Thoracic Society. Guideline for oxygen use in adults in healthcare and emergency settings. [17] World Health Organization. Clinical treatment guideline for tobacco cessation in adults. [18] National Institute for Health and Care Excellence. Treating tobacco dependence (NG209, updated 2025). [19] COPD Foundation/Alpha-1 Foundation. Diagnosis and management of alpha-1 antitrypsin deficiency in the adult.
GC040 Cough And Wheezing: Asthma And Allergic Lung Diseases
Asthma and allergic lung diseases are chronic inflammatory airway disorders characterized by reversible bronchoconstriction, mucus hypersecretion, and airway hyperresponsiveness, presenting with episodic cough, wheezing, and dyspnea triggered by allergens or irritants.
GC042 Deterioration Of Eyesight In A Diabetic Patient Diabetic Complications
Progressive visual impairment in a diabetic patient resulting from complications such as diabetic retinopathy, macular edema, or accelerated cataract formation due to chronic hyperglycemia-induced microvascular and lens damage.